Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathieu Boulin

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Bulletin Du Cancer|February 19, 2025
[French mapping of clinical pharmacy activities for older patients with cancer: A SFPO-SFPC survey]Chloé Herledan, Anne Toulemonde, Mathilde Sturmia, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 18, 2020
Clinical and economic impact of pharmacist interventions in an ambulatory hematology-oncology departmentJonathan de Grégori, Pauline Pistre, Meredith Boutet, et al.
Journal of Hepatology|February 11, 2018
Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trialBoris Guiu, Jean-Louis Jouve, Antonin Schmitt, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 28, 2014
Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinomaMathieu Boulin, Héloïse Adam, Boris Guiu, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 2, 2011
Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinomaMathieu Boulin, Anne Ciboulet, Boris Guiu, et al.
American Journal of Clinical Oncology|April 8, 2009
Pilot study of transarterial chemoembolization with pirarubicin and amiodarone for unresectable hepatocellular carcinomaBoris Guiu, Cédric Colin, Jean-Pierre Cercueil, et al.
Cancers|May 28, 2022
Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma PatientsMadeline Devaux, Mathieu Boulin, Morgane Mounier, et al.
Acta Diabetologica|January 13, 2023
Glycemic control in people with diabetes treated with cancer chemotherapy: contribution of continuous glucose monitoringPauline Legris, Benjamin Bouillet, Justine Pâris, et al.
International Journal of Environmental Research and Public Health|April 12, 2022
COVID-19 Lockdown in Patients with Chronic Diseases: A Cross-Sectional StudyMathieu Boulin, Amélie Cransac-Miet, Marc Maynadié, et al.
Radiology|May 1, 2019
Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II TrialBoris Guiu, Patrick Chevallier, Eric Assenat, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Bulletin Du Cancer|February 19, 2025
[French mapping of clinical pharmacy activities for older patients with cancer: A SFPO-SFPC survey]Chloé Herledan, Anne Toulemonde, Mathilde Sturmia, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 18, 2020
Clinical and economic impact of pharmacist interventions in an ambulatory hematology-oncology departmentJonathan de Grégori, Pauline Pistre, Meredith Boutet, et al.
Journal of Hepatology|February 11, 2018
Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trialBoris Guiu, Jean-Louis Jouve, Antonin Schmitt, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 28, 2014
Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinomaMathieu Boulin, Héloïse Adam, Boris Guiu, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 2, 2011
Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinomaMathieu Boulin, Anne Ciboulet, Boris Guiu, et al.
American Journal of Clinical Oncology|April 8, 2009
Pilot study of transarterial chemoembolization with pirarubicin and amiodarone for unresectable hepatocellular carcinomaBoris Guiu, Cédric Colin, Jean-Pierre Cercueil, et al.
Cancers|May 28, 2022
Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma PatientsMadeline Devaux, Mathieu Boulin, Morgane Mounier, et al.
Acta Diabetologica|January 13, 2023
Glycemic control in people with diabetes treated with cancer chemotherapy: contribution of continuous glucose monitoringPauline Legris, Benjamin Bouillet, Justine Pâris, et al.
International Journal of Environmental Research and Public Health|April 12, 2022
COVID-19 Lockdown in Patients with Chronic Diseases: A Cross-Sectional StudyMathieu Boulin, Amélie Cransac-Miet, Marc Maynadié, et al.
Radiology|May 1, 2019
Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II TrialBoris Guiu, Patrick Chevallier, Eric Assenat, et al.
Pageof 6